What's Hot

View all perspectives
      One for you, one for me!
      So many pasalubong char
      @RHEUMarampa
      @RheumNow
      #acr23 #ACRambassador https://t.co/v0mZ9vbad

      Lisa 🐳🗺🧭 rheumarhyme

      1 year ago
      One for you, one for me! So many pasalubong char @RHEUMarampa @RheumNow #acr23 #ACRambassador https://t.co/v0mZ9vbadx
      Cellular based biology explanation of sex bias in ARDs 👀

      Data from AMP w/ sc-RNA seq from synovial tissue shows:

      E

      Aurelie Najm

      1 year ago
      Cellular based biology explanation of sex bias in ARDs 👀 Data from AMP w/ sc-RNA seq from synovial tissue shows: Enriched inflammatory pathways in females synovial macrophages clusters vs. males Basis for gender specific treatment strategies? @RheumNow ABST0724 #ACR23 https://t.co/1p8PDIRNoI
      Is there a difference in secukinumab vs. adalimumab biosimilar on radiographic progression in a subgroup of axSpA pts wi

      Robert B Chao, MD

      1 year ago
      Is there a difference in secukinumab vs. adalimumab biosimilar on radiographic progression in a subgroup of axSpA pts with syndesmophytes or CRP levels? Radiographic progression equally low in both drugs NO difference in syndesmophytes or CRP @RheumNow #ACR23 Abs#0522 https://t.co/1TBKAxuKPE
      In their study, Dr Deng et al identified TRAF5 as susceptible gene for SLE-PAH
      ✳️TRAF5 deficiency activates BMP/TGFB

      sheila

      1 year ago
      In their study, Dr Deng et al identified TRAF5 as susceptible gene for SLE-PAH ✳️TRAF5 deficiency activates BMP/TGFB signaling w/⬆️PAEC apoptosis ✳️TRAF5 overexpression attenuated PAH sxs in mice TRAF5 as potential BM for dx/novel tx target in SLE-PAH? #ACR23 ABST0723 @RheumNow https://t.co/WT9vQo8y8s
      Important plenary re:reduced vs standard GC for AAV... IRL

      PEXIVAS & recent guidelines supported low dose taper

      Re

      Mike Putman EBRheum

      1 year ago
      Important plenary re:reduced vs standard GC for AAV... IRL PEXIVAS & recent guidelines supported low dose taper Real world data w/severe dx? Increased risk of death & ESKD for REDUCED pts Need full data but yikes... @RheumNow #ACR23 #ACRBest https://t.co/3S23O9d1ok
      Abst#0725 #ACR23 @RheumNow
      PEXIVAS Real life data!
      GPA & MPA pts - Retrosp observ study
      ⭐️Reduced-dose GC regime

      Eric Dein

      1 year ago
      Abst#0725 #ACR23 @RheumNow PEXIVAS Real life data! GPA & MPA pts - Retrosp observ study ⭐️Reduced-dose GC regimen ass w/ INCREASED risk of death, ESKD, progression Greatest risk: pt w Cr levels >300 umol/L, RTX induction Rx ⚠️Caution w/ reduced GC, RTX, severe kidney dis #ACRBest https://t.co/7qI5c1ZiqO
      Look who I interviewed for @RheumNow!!@ashira_md shares the story of APOL1 effects on SLE . Patients with the variants h

      TheDaoIndex KDAO2011

      1 year ago
      Look who I interviewed for @RheumNow!!@ashira_md shares the story of APOL1 effects on SLE . Patients with the variants have more aggressive renal and vascular disease. #DuboisLecture #ACR23 #StrongWomen #FutureNobelRecipient https://t.co/IzRsHwaMIb
      Interesting study on PEXIVAS reduced steroid use from today's plenary session!
      Reduced steroid dose in GPA/MPA pts assoc

      Robert B Chao, MD

      1 year ago
      Interesting study on PEXIVAS reduced steroid use from today's plenary session! Reduced steroid dose in GPA/MPA pts associated w/ INCREASED risk of death, ESKD, progression of dz Even greater risk in pts with higher Cr lvls or RTX induction use @RheumNow #ACR23 Abs#0725 #ACRbest https://t.co/frsOrANKhf
      In this real world EHR-based SLE cohort, AJorge: BEL was assoc w/⬇️risk of damage prog vs. MMF (HR 0.74 [95% CI 0.67

      sheila

      1 year ago
      In this real world EHR-based SLE cohort, AJorge: BEL was assoc w/⬇️risk of damage prog vs. MMF (HR 0.74 [95% CI 0.67-0.83) but no diff bet BEL vs. MTX/AZA at 3yrs Further prospective studies req'd? BEL remains an option for non-renal SLE tx. #ACR23 ABST0606 @RheumNow https://t.co/KabBeXKpvk
      Did you know?
      👉APOL1 variants are protective against trypanosomiasis.
      👉Despite reassuring renal biopsies, SLE pts

      TheDaoIndex KDAO2011

      1 year ago
      Did you know? 👉APOL1 variants are protective against trypanosomiasis. 👉Despite reassuring renal biopsies, SLE pts with #APOL1 variants had: ⬆️progression to ESRD, ⬆️atherosclerosis, ⬆️osteonecrosis (likely related to endothel dysfnx) #ACR23 @ashira_md @RheumNow #DuboisLecture https://t.co/w1lnGMPFAQ
      Abs#0726 #ACR23 @RheumNow
      MSUS recs in Canadian Rheum training 🇨🇦:
      Focus MSUS exam of hands/wrists/feet: ID effus

      Eric Dein

      1 year ago
      Abs#0726 #ACR23 @RheumNow MSUS recs in Canadian Rheum training 🇨🇦: Focus MSUS exam of hands/wrists/feet: ID effusion, synov, erosions v osteophyte, tenosyn Limited MSUS of knee/ankle for effusion @USSONAR_Rh @MymaAlbaydaMD Agree: MSUS should be part of rheum training for all https://t.co/UNPpAA1p0V
      Real world data on low dose PEXIVAS steroid by Nagle et al. Increased risk of progression/relapse/death/ESKD in those wi

      Richard Conway

      1 year ago
      Real world data on low dose PEXIVAS steroid by Nagle et al. Increased risk of progression/relapse/death/ESKD in those with severe GPA/MPA HR 1.72. More marked in those with creat>300 or with RTX induction Abstr#0725 #ACR23 @RheumNow https://t.co/vTXVZfjbXx https://t.co/4FuMjxOuyB
      Should there be a minimum ultrasound training as competencies in rheumatology training? Abst0726 #ACR23 ⁦@ACRheum⁩ ?

      Janet Pope

      1 year ago
      Should there be a minimum ultrasound training as competencies in rheumatology training? Abst0726 #ACR23 ⁦@ACRheum⁩ ⁦@RheumNow⁩ #RheumEd #POCUS https://t.co/mqdcPEeMYW
      INVIGORATE-2 RCT of IV secukinumab in PsA. Demonstrates efficacy as expected. My big question is why are we doing trials

      Richard Conway

      1 year ago
      INVIGORATE-2 RCT of IV secukinumab in PsA. Demonstrates efficacy as expected. My big question is why are we doing trials like this against placebo? Surely a non-inferiority vs s/c secukinumab is more ethical. Abstr#0776 #ACR23 @RheumNow https://t.co/Usw0iwZEF5 https://t.co/DP6Gb4pF8a
      Do you think point of care #ultrasound should be mandatory in #rheumatologu #residency #training? @RheumNow @ACRheum #A

      Janet Pope

      1 year ago
      Do you think point of care #ultrasound should be mandatory in #rheumatologu #residency #training? @RheumNow @ACRheum #ACR23

      Podcasts

      • ACR24 PsA Topic Panel Advancing Care for Psoriatic Arthritis
      • ACR 2024 Rheumatology Roundup Featuring Drs. Artie Kavanaugh and Jack Cush
      • ACR24 SpA Topic Panel Key Discussions on Spondyloarthritis

      Catch up on Conference Podcasts

      Key Conference Topics

      Additional Topics

      Filter by Type

      Featured Video

      Do you get our email newsletter?

      Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

      This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

      Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

      Copyright {{ 'now'|date('Y') }} All Rights Reserved.